These findings suggest that the reduced expression of Sirt6 and concordant increases in acetylation, and thus XBP1s expression, contribute to the disease progression of NAFLD in patients. The gene discussed is SIRT6; the disease is metabolic dysfunction-associated steatotic liver disease.